23.02

5.46% -1.33

After Hours: 23.02

Denali Therapeutics Inc (DNLI)

Overview News Price History Option Chain Financials Why DNLI Down? Discussions Forecast

Denali Therapeutics Inc stock is traded at $23.02, with a volume of 1.23M. It is down -5.46% in the last 24 hours and down -10.50% over the past month. Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.

Previous Close:

$24.35

Open:

$24.34

24h Volume:

1.23M

Relative Volume:

0.66

Market Cap:

$3.65B

Revenue:

$1.27M

Net Income/Loss:

$-508.02M

P/E Ratio:

-7.9911

EPS:

-2.8807

Net Cash Flow:

$-419.23M

1W Performance:

-0.39%

1M Performance:

-10.50%

6M Performance:

+5.89%

1Y Performance:

+66.45%

1-Day Range:

$22.99

$24.35

1-Week Range:

$22.99

$24.68

52-Week Range:

$12.58

$27.30

Denali Therapeutics Inc Stock (DNLI) Company Profile

Name

Denali Therapeutics Inc

Sector

Healthcare (1079)

Industry

Biotechnology (598)

Phone

(650) 866-8547

Address

161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO

Employee

507

Twitter

Next Earnings Date

2026-08-10

Latest SEC Filings

DNLI's Discussions on Twitter

Compare DNLI vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DNLI Denali Therapeutics Inc	23.02	3.74B	1.27M	-508.02M	-419.23M	-2.8807
VRTX Vertex Pharmaceuticals Inc	477.10	121.57B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	762.63	69.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	853.82	55.61B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	187.53	39.98B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	316.01	33.81B	5.76B	514.49M	1.10B	4.4813

Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-26-26	Reiterated	H.C. Wainwright	Buy
Feb-24-26	Initiated	Wolfe Research	Peer Perform
Jan-07-26	Resumed	UBS	Buy
Apr-10-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Mar-07-25	Resumed	Morgan Stanley	Overweight
Feb-11-25	Initiated	Deutsche Bank	Buy
Jan-07-25	Initiated	Robert W. Baird	Outperform
Jan-03-25	Initiated	William Blair	Outperform
Dec-16-24	Upgrade	Stifel	Hold → Buy
Oct-10-24	Resumed	Raymond James	Mkt Perform
Oct-07-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Dec-13-23	Initiated	Citigroup	Buy
Nov-20-23	Resumed	JP Morgan	Overweight
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight
Sep-06-23	Initiated	B. Riley Securities	Buy
Jan-30-23	Initiated	SVB Securities	Outperform
Dec-05-22	Initiated	Cowen	Outperform
Nov-02-22	Upgrade	BTIG Research	Neutral → Buy
Nov-02-22	Initiated	BofA Securities	Buy
Jun-23-22	Initiated	Berenberg	Buy
Dec-10-21	Resumed	Raymond James	Mkt Perform
Sep-21-21	Initiated	Oppenheimer	Outperform
Sep-01-21	Initiated	SMBC Nikko	Outperform
May-18-21	Initiated	UBS	Buy
Feb-26-21	Reiterated	H.C. Wainwright	Buy
Feb-10-21	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-11-20	Reiterated	H.C. Wainwright	Buy
Oct-16-20	Downgrade	BTIG Research	Buy → Neutral
Sep-14-20	Resumed	JP Morgan	Overweight
Aug-20-20	Reiterated	H.C. Wainwright	Buy
Mar-13-20	Upgrade	Evercore ISI	In-line → Outperform
Feb-28-20	Upgrade	Wedbush	Neutral → Outperform
Feb-24-20	Initiated	Jefferies	Buy
Feb-19-20	Initiated	Stifel	Hold
Jan-27-20	Upgrade	Goldman	Neutral → Buy
Sep-26-19	Initiated	Wedbush	Neutral
Sep-13-19	Initiated	Nomura	Buy
Aug-09-19	Initiated	BTIG Research	Buy
Jun-26-19	Initiated	H.C. Wainwright	Buy
Nov-15-18	Initiated	Cantor Fitzgerald	Overweight
Nov-12-18	Initiated	Janney	Buy
Mar-12-18	Downgrade	Evercore ISI	Outperform → In-line
Jan-02-18	Initiated	Evercore ISI	Outperform
Jan-02-18	Initiated	Goldman	Neutral
Jan-02-18	Initiated	JP Morgan	Overweight
Jan-02-18	Initiated	Morgan Stanley	Overweight

View All

Denali Therapeutics Inc Stock (DNLI) Latest News

Jul 28, 2026

Denali Therapeutics sells priority review voucher for $195 million gross proceeds - Bitget

Jul 28, 2026

Jul 27, 2026